Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Publications
2 shownPatisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number,...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 3,520
- Institution
- University College London
External Links
Identifiers
- ORCID
- 0000-0002-6983-9598
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.